How to use antibodies to control chemical reactions
Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies
antibodies are remarkable biomarkers: they are the cues that provide us with indications about many diseases and how our immune system counter them. Now a group of scientists from the University of Rome, Tor Vergata (Italy) has found a way to repurpose them so that they can trigger a specific chemical reaction.
Artistic representation of two antibodies triggering two chemical reactions.
Illustration by Oscar Melendre Hoyos
"We demonstrated a strategy to use specific antibodies to control chemical reactions forming a wide range of molecules, from imaging to therapeutic agents." says Francesco Ricci, full professor at the University of Rome Tor Vergata and senior author of the article. "Our approach allows to synthesize a functional molecule from inactive precursors only when a specific antibody is present in the reaction mixture".
To achieve this goal, the researchers took advantage of the versatility of synthetic DNA oligonucleotides and of the predictability of DNA-DNA interactions. "Synthetic oligonucleotides are amazing molecules, they can be modified with a range of reactive groups and also with recognition elements that can target specific antibodies." says Lorena Baranda, PhD student in the group of Prof. Ricci and first author of the article. "In our work we rationally designed and synthesized a pair of modified DNA sequences that can recognize a specific antibody and bind to it. When this happens the reactive groups appended on the other ends of the DNA strands will be in close proximity and their reaction will be triggered ultimately leading to the formation of a chemical product", she explains.
The strategy demonstrated in this work can be used, for example, to control the formation of functional molecules, such as therapeutic agents, with biomarker antibodies. As a proof of principle of this possible application the researchers demonstrated the formation of an anticoagulant drug able to inhibit the activity of thrombin, a key enzyme of blood coagulation and an important target for the treatment of thrombosis. "We demonstrated that a specific IgG antibody can trigger the formation of the anticoagulant agent, which was further proven to efficiently inhibit the activity of thrombin" says Prof. Ricci. "The strategy is highly specific to the antibody of interest and also programmable. We envision it would represent a new avenue to targeted therapy and diagnostics", he concludes.
Original publication
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Artificial intelligence could improve therapy for lymphoma
Category:Psilocybe
A fungus converts cellulose directly into a novel platform chemical - A new process for the mass production of erythro-isocitric acid from waste could make the substance interesting for industry in the future
Bruker Announces Acquisition of Inscopix for Neuroscience Research - Head-Mounted Miniscopes Expand Neural Functional Imaging Capabilities
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration - Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Hopes of a New Treatment Approach for Paralysis
KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform - AstriVax to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection
Manufacturers in the laboratory sector choose analytica - Large number of exhibitors registered more than a year before analytica
Eurofins agrees to acquire SYNLAB’s clinical diagnostics operations in Spain
Hepatocellular_carcinoma
Paget's_disease_of_the_breast
